Literature DB >> 15250915

Volume-independent mechanisms of hypertension in hemodialysis patients: clinical implications.

Peter J Blankestijn1, Gerry Ligtenberg.   

Abstract

The renin-angiotensin and sympathetic nervous systems are often activated in hemodialysis (HD) patients; the pathogenesis of this condition is discussed. Medications aimed at reducing renin and sympathetic activity may improve the cardiovascular prognosis, independent of its effect on blood pressure. This knowledge has important implications for the choice of treatment in HD patients.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15250915     DOI： 10.1111/j.0894-0959.2004.17324.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN： 0894-0959            Impact factor:   3.455


  10 in total

1.  Effects of frequent hemodialysis on blood pressure: Results from the randomized frequent hemodialysis network trials.

Authors:  Peter Kotanko; Amit X Garg; Tom Depner; Andreas Pierratos; Christopher T Chan; Nathan W Levin; Tom Greene; Brett Larive; Gerald J Beck; Jennifer Gassman; Alan S Kliger; John B Stokes
Journal:  Hemodial Int       Date:  2015-01-05       Impact factor: 1.812

2.  Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial.

Authors:  Rajiv Agarwal; Arjun D Sinha; Maria K Pappas; Terri N Abraham; Getachew G Tegegne
Journal:  Nephrol Dial Transplant       Date:  2014-01-06       Impact factor: 5.992

Review 3.  The controversies of diagnosing and treating hypertension among hemodialysis patients.

Authors:  Rajiv Agarwal
Journal:  Semin Dial       Date:  2012-06-11       Impact factor: 3.455

4.  Pharmacokinetics and antihypertensive effects of candesartan cilexetil in patients undergoing haemodialysis: an open-label, single-centre study.

Authors:  Egbert Godehard Schulz; Shadfar Bahri; Volker Schettler; Aron-Frederik Popov; Matthias Hermann
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

5.  Impact of renal artery stent implantation on hypertension in patients with hemodialysis.

Authors:  Hiroyuki Hikita; Keisuke Kojima; Shigeki Kimura; Atsushi Takahashi; Mitsuaki Isobe
Journal:  Int J Angiol       Date:  2014-06

6.  Long-term effects of aliskiren on blood pressure and the renin-angiotensin-aldosterone system in hypertensive hemodialysis patients.

Authors:  Yoshiyuki Morishita; Minami Watanabe; Shiho Hanawa; Osamu Iimura; Sadao Tsunematsu; Kenichi Ishibashi; Eiji Kusano
Journal:  Int J Nephrol Renovasc Dis       Date:  2012-03-21

7.  Rationale and design of the Sodium Lowering In Dialysate (SoLID) trial: a randomised controlled trial of low versus standard dialysate sodium concentration during hemodialysis for regression of left ventricular mass.

Authors:  Joanna Leigh Dunlop; Alain Charles Vandal; Janak Rashme de Zoysa; Ruvin Sampath Gabriel; Imad Adbi Haloob; Christopher John Hood; Philip James Matheson; David Owen Ross McGregor; Kannaiyan Samuel Rabindranath; David John Semple; Mark Roger Marshall
Journal:  BMC Nephrol       Date:  2013-07-15       Impact factor: 2.388

8.  Hypertension control among euvolemic hypertensive hemodialysis patients in Malaysia: a prospective follow-up study.

Authors:  Amjad Khan; Amer Hayat Khan; Azreen Syazril Adnan; Syed Azhar Syed Sulaiman; Saima Mushtaq; Nafees Ahmad; Irfanullah Khan
Journal:  J Pharm Policy Pract       Date:  2019-05-14

9.  Safely reducing haemodialysis frequency during the COVID-19 pandemic.

Authors:  Michelle Da Silva Lodge; Thilini Abeygunaratne; Helen Alderson; Ibrahim Ali; Nina Brown; Constantina Chrysochou; Rosie Donne; Ibi Erekosima; Philip Evans; Emma Flanagan; Simon Gray; Darren Green; Janet Hegarty; Audrey Hyde; Philip A Kalra; Elizabeth Lamerton; David Lewis; Rachel Middleton; David New; Robert Nipah; Donal O'Donoghue; Edmond O'Riordan; Dimitrios Poulikakos; Francesco Rainone; Maharajan Raman; James Ritchie; Smeeta Sinha; Grahame Wood; J Tollitt
Journal:  BMC Nephrol       Date:  2020-12-07       Impact factor: 2.388

10.  Direct Renin inhibitor: aliskiren in chronic kidney disease.

Authors:  Yoshiyuki Morishita; Eiji Kusano
Journal:  Nephrourol Mon       Date:  2012-12-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.